insitro retains global rights in Lilly deals

This structure turns insitro from a fee earning discovery vendor into a company with real shots on goal in drug sales. In the Lilly deals, insitro uses Lilly's delivery hardware for getting RNA medicines into liver cells and can tap Lilly's antibody development know how, but it keeps worldwide control of the resulting programs after candidate nomination. That means Lilly gets milestones and royalties, while insitro keeps the bigger upside and takes on the expensive clinical and commercial work.1 2

• The liver delivery piece is concrete. Lilly gives insitro an option to in license clinical stage GalNAc technology, which is the targeting tag used to carry siRNA into liver cells. That lets insitro pair its own genetically selected targets and RNA molecules with a delivery system that already exists, instead of inventing both the drug and the package at once.1 3
• The antibody collaboration follows the same logic. Lilly helps discover and develop an antibody against a third metabolic disease target, but insitro still retains global rights to its own programs. Compared with partner led models, this keeps more long term economics inside insitro and makes the company look closer to an asset owner like Isomorphic Labs or Genesis, not just a platform contractor.1 4 5
• The tradeoff is capital intensity. insitro has raised about $629M in estimated funding, but owning programs means paying for toxicology, manufacturing, trials, and launch preparation later on. The economics improve if a drug works, yet the company also carries much more balance sheet risk than in a pure collaboration where the pharma partner funds most downstream development.2 6

The likely next step is a more mixed model, where insitro keeps the highest conviction liver and metabolic assets, then uses selective partnerships only for pieces like delivery, manufacturing, or regional commercialization. If early owned programs reach the clinic in 2027 as planned, the company shifts from proving its AI can find targets to proving it can compound value by owning more of the medicine itself.2 7